PFKFB3 and neoplasm: Targeting PFKFB3-mediated glycolytic energy supply for tumor angiogenesis represents a distinct, potentially superior anti-angiogenic strategy, compared to molecularly targeting individual pro-angiogenic drivers [8, 13].